Stocktoria

Mineralys Therapeutics, Inc. MLYS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-02-10

Mineralys Therapeutics, Inc. statistics & valuation

Market cap$2.4B
P / B3.6×
Return on equity-23.9%
Return on capital-26.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2022202320242025
Operating margin (%)
2022202320242025
Return on equity (%)
-29.80% -93.00% -23.90% 2022202320242025
Shares outstanding
6.4M 41.1M 49.8M 81.5M 2022202320242025
Net debt ($)
2022202320242025
Share buybacks ($)
2022202320242025
Return on assets (%)
-26.00% -28.60% -86.40% -23.40% 2022202320242025
Free cash flow margin (%)
2022202320242025
Debt / equity (×)
2022202320242025
EPS ($)
-$5.77 -$1.99 -$3.66 -$2.29 2022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022
Return on assets-23.4%-86.4%-28.6%-26.0%
Return on equity-23.9%-93.0%-29.8%57.0%
Current ratio43.7614.0223.7613.98

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.